Publications (42) FRANCISCO OLMO ARÉVALO publications

2023

  1. Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice

    PLoS Pathogens, Vol. 19, Núm. 11 November

  2. Bis-6-amidino-benzothiazole Derivative that Cures Experimental Stage 1 African Trypanosomiasis with a Single Dose

    Journal of medicinal chemistry, Vol. 66, Núm. 18, pp. 13043-13057

  3. Dissecting the interstrand crosslink DNA repair system of Trypanosoma cruzi

    DNA Repair, Vol. 125

  4. Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen

    Frontiers in Tropical Diseases, Vol. 4

2021

  1. Bioluminescent:Fluorescent trypanosoma cruzi reporter strains as tools for exploring chagas disease pathogenesis and drug activity

    Current Pharmaceutical Design, Vol. 27, Núm. 14, pp. 1733-1740

  2. Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease

    European Journal of Medicinal Chemistry, Vol. 223

  3. Image-based in vitro screening reveals the trypanostatic activity of hydroxymethylnitrofurazone against trypanosoma cruzi

    International Journal of Molecular Sciences, Vol. 22, Núm. 13

  4. Local association of Trypanosoma cruzi chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale

    PLoS Pathogens, Vol. 17, Núm. 8

  5. Quantifying traffic, biomass burning and secondary source contributions to atmospheric particle number concentrations at urban and suburban sites

    Science of the Total Environment, Vol. 768

2020

  1. Challenges in Chagas Disease Drug Development

    Molecules, Vol. 25, Núm. 12

  2. Drug-cured experimental trypanosoma cruzi infections confer long-lasting and crossstrain protection

    PLoS Neglected Tropical Diseases, Vol. 14, Núm. 4, pp. 1-20

  3. Intracellular dna replication and differentiation of trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infection

    PLoS Neglected Tropical Diseases, Vol. 14, Núm. 3

  4. Non-invasive monitoring of drug action: A new live in vitro assay design for chagas’ disease drug discovery

    PLoS Neglected Tropical Diseases, Vol. 14, Núm. 7, pp. 1-17

  5. Trypanosoma cruzi amastigotes that persist in the colon during chronic stage murine infections have a reduced replication rate: Trypanosoma cruzi proliferation

    Open Biology, Vol. 10, Núm. 12

2019

  1. Exploiting genetically modified dual-reporter strains to monitor experimental trypanosoma cruzi infections and host-parasite interactions

    Methods in Molecular Biology (Humana Press Inc.), pp. 147-163

2018

  1. Activity in vitro and in vivo against Trypanosoma cruzi of a furofuran lignan isolated from Piper jericoense

    Experimental Parasitology, Vol. 189, pp. 34-42

  2. Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping

    PLoS Neglected Tropical Diseases, Vol. 12, Núm. 4

  3. Optimising genetic transformation of Trypanosoma cruzi using hydroxyurea-induced cell-cycle synchronisation

    Molecular and Biochemical Parasitology, Vol. 226, pp. 34-36

2017

  1. Simple dialkyl pyrazole-3,5-dicarboxylates show in vitro and in vivo activity against disease-causing trypanosomatids

    Parasitology, Vol. 144, Núm. 9, pp. 1133-1143

  2. Tetradentate polyamines as efficient metallodrugs for Chagas disease treatment in murine model

    Journal of Chemotherapy, Vol. 29, Núm. 2, pp. 83-93